NCT00159783View on ClinicalTrials.gov

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Bipolar Disorder
Interventions
DRUG

asenapine

Asenapine, 40 weeks

DRUG

Olanzapine

Olanzapine, 40 weeks

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Organon and Co

INDUSTRY